布罗卢izumab治疗视网膜静脉阻塞（RVO）所致顽固性黄斑水肿的真实世界经验：12个月随访——一项试点研究 - Suppr

Suppr

超能文献

Real world experience of brolucizumab in recalcitrant macular edema in retinal vein occlusions (RVO's): 12 months follow up - A pilot study.

作者信息

Narnaware Shilpi H, Bawankule Prashant K, Raje Dhananjay, Jagdhane Prerna, Nagdeve Rakesh

机构信息

Sarakshi Netralaya, 19, Rajiv Nagar, Wardha Road, Nagpur, Maharashtra, India.

Data Analysis Group, MDS Bio-Analytics Pvt. Ltd., Nagpur, Maharashtra, India.

出版信息

Indian J Ophthalmol. 2024 Dec 1;72(12):1829-1832. doi: 10.4103/IJO.IJO_650_24. Epub 2024 Nov 29.

DOI:10.4103/IJO.IJO_650_24

PMID:39620686

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11727943/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6489/11727943/031b3b90b483/IJO-72-1829-g001.jpg

相似文献

Real world experience of brolucizumab in recalcitrant macular edema in retinal vein occlusions (RVO's): 12 months follow up - A pilot study.布罗卢izumab治疗视网膜静脉阻塞（RVO）所致顽固性黄斑水肿的真实世界经验：12个月随访——一项试点研究

Indian J Ophthalmol. 2024 Dec 1;72(12):1829-1832. doi: 10.4103/IJO.IJO_650_24. Epub 2024 Nov 29.

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series.玻璃体内注射布罗珠单抗治疗顽固性糖尿病性黄斑水肿的超说明书应用：一项真实世界病例系列研究

Am J Ophthalmol Case Rep. 2021 Sep 1;24:101197. doi: 10.1016/j.ajoc.2021.101197. eCollection 2021 Dec.

Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.在初治和治疗难治性糖尿病性黄斑水肿患者中，布罗鲁单抗与阿柏西普对比的真实世界经验。

J Clin Med. 2024 Mar 21;13(6):1819. doi: 10.3390/jcm13061819.

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study.在印度真实世界场景中，布罗利珠单抗与阿柏西普治疗顽固性糖尿病性黄斑水肿的比较——BRADIR研究

Am J Ophthalmol Case Rep. 2024 Aug 23;36:102152. doi: 10.1016/j.ajoc.2024.102152. eCollection 2024 Dec.

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series.玻璃体内注射布罗珠单抗治疗视网膜中央静脉阻塞所致顽固性黄斑水肿：一项小型病例系列研究

Case Rep Ophthalmol. 2022 Nov 17;13(3):921-928. doi: 10.1159/000526710. eCollection 2022 Sep-Dec.

Off label intravitreal Brolucizumab in treatment of recurrent macular edema due to branch retinal vein occlusion: A case report.眼内注射 Brolucizumab 治疗分支视网膜静脉阻塞继发黄斑水肿复发：一例报告。

Photodiagnosis Photodyn Ther. 2022 Mar;37:102694. doi: 10.1016/j.pdpdt.2021.102694. Epub 2021 Dec 16.

[Recurrence of macular edema complicating central retinal vein occlusion: Consider follow-up fluorescein angiography].黄斑水肿复发并发视网膜中央静脉阻塞：考虑进行随访荧光素血管造影

J Fr Ophtalmol. 2020 Apr;43(4):305-311. doi: 10.1016/j.jfo.2019.08.014. Epub 2020 Feb 20.

Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.雷珠单抗治疗新生血管性年龄相关性黄斑变性超过2年的真实世界经验：REBA扩展研究

Graefes Arch Clin Exp Ophthalmol. 2024 Apr;262(4):1161-1167. doi: 10.1007/s00417-023-06329-1. Epub 2023 Dec 8.

Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.Brolucizumab 治疗难治性新生血管性年龄相关性黄斑变性的真实世界数据：中国人群研究。

PLoS One. 2024 Apr 2;19(4):e0301096. doi: 10.1371/journal.pone.0301096. eCollection 2024.

Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.玻璃体内注射布罗利珠单抗治疗新生血管性年龄相关性黄斑变性的短期安全性和有效性：一项多中心回顾性真实世界研究。

Ophthalmologica. 2023;246(3-4):192-202. doi: 10.1159/000529410. Epub 2023 Jan 31.

本文引用的文献

Case Rep Ophthalmol. 2022 Nov 17;13(3):921-928. doi: 10.1159/000526710. eCollection 2022 Sep-Dec.

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.MERLIN：一项多中心、随机、双盲的 3a 期临床试验，评估 Brolucizumab 在伴有新生血管性年龄相关性黄斑变性和持续性视网膜液的患者中的疗效。

Ophthalmology. 2022 Sep;129(9):974-985. doi: 10.1016/j.ophtha.2022.04.028. Epub 2022 May 7.

Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk.布罗利尤单抗——终止四周一次给药试验——重新平衡免疫原性风险。

Expert Opin Biol Ther. 2022 Apr;22(4):441-443. doi: 10.1080/14712598.2022.2028772. Epub 2022 Jan 24.

Photodiagnosis Photodyn Ther. 2022 Mar;37:102694. doi: 10.1016/j.pdpdt.2021.102694. Epub 2021 Dec 16.

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK和HARRIER：布罗鲁单抗治疗新生血管性年龄相关性黄斑变性3期试验的96周结果

Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20.

A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE).一项评估布罗鲁单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力损害患者的疗效和安全性的随机、双盲、多中心、III期研究（KITE）。

Klin Monbl Augenheilkd. 2020 Apr;237(4):450-453. doi: 10.1055/a-1101-9126. Epub 2020 Mar 4.

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study.真实世界数据：OCEAN研究中雷珠单抗治疗视网膜静脉阻塞的情况

Clin Ophthalmol. 2019 Nov 7;13:2167-2179. doi: 10.2147/OPTH.S209253. eCollection 2019.

Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions.抗血管内皮生长因子玻璃体内注射疗法治疗视网膜静脉阻塞的最新进展

Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):546-553. doi: 10.22608/APO.2017459.

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion.视网膜分支静脉阻塞的分类、发病机制、危险因素、自然史及治疗的新进展

J Ophthalmol. 2017;2017:4936924. doi: 10.1155/2017/4936924. Epub 2017 Mar 12.

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.雷珠单抗与地塞米松治疗视网膜中央静脉阻塞的临床疗效和安全性（COMRADE C）：一项欧洲标签研究。

Am J Ophthalmol. 2016 Sep;169:258-267. doi: 10.1016/j.ajo.2016.04.020. Epub 2016 May 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验